[HTML][HTML] Recent advances in the development of protein–protein interactions modulators: mechanisms and clinical trials

H Lu, Q Zhou, J He, Z Jiang, C Peng, R Tong… - Signal transduction and …, 2020 - nature.com
Protein–protein interactions (PPIs) have pivotal roles in life processes. The studies showed
that aberrant PPIs are associated with various diseases, including cancer, infectious …

[HTML][HTML] Strategies to inhibit Myc and their clinical applicability

JR Whitfield, ME Beaulieu, L Soucek - Frontiers in cell and …, 2017 - frontiersin.org
Myc is an oncogene deregulated in most—perhaps all—human cancers. Each Myc family
member, c-, L-, and N-Myc, has been connected to tumor progression and maintenance …

[HTML][HTML] Mission possible: advances in MYC therapeutic targeting in cancer

BL Allen-Petersen, RC Sears - BioDrugs, 2019 - Springer
MYC is a master transcriptional regulator that controls almost all cellular processes. Over the
last several decades, researchers have strived to define the context-dependent …

[HTML][HTML] Therapeutic inhibition of Myc in cancer. Structural bases and computer-aided drug discovery approaches

LA Carabet, PS Rennie, A Cherkasov - International journal of molecular …, 2018 - mdpi.com
Myc (avian myelocytomatosis viral oncogene homolog) represents one of the most sought
after drug targets in cancer. Myc transcription factor is an essential regulator of cell growth …

Pathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseases

VN Uversky, V Davé, LM Iakoucheva… - Chemical …, 2014 - ACS Publications
Pathological Unfoldomics of Uncontrolled Chaos: Intrinsically Disordered Proteins and Human
Diseases | Chemical Reviews ACS ACS Publications C&EN CAS Find my institution Log In …

[HTML][HTML] Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc

SK Madden, AD de Araujo, M Gerhardt, DP Fairlie… - Molecular Cancer, 2021 - Springer
Abstract c-Myc is a transcription factor that is constitutively and aberrantly expressed in over
70% of human cancers. Its direct inhibition has been shown to trigger rapid tumor regression …

[HTML][HTML] Small molecules targeting c-Myc oncogene: promising anti-cancer therapeutics

BJ Chen, YL Wu, Y Tanaka, W Zhang - International journal of …, 2014 - ncbi.nlm.nih.gov
The nuclear transcription factor c-Myc is a member of the Myc gene family with multiple
functions and located on band q24. 1 of chromosome 8. The c-Myc gene is activated by …

Small-molecule inhibitors of the Myc oncoprotein

S Fletcher, EV Prochownik - Biochimica Et Biophysica Acta (BBA)-Gene …, 2015 - Elsevier
Abstract The c-Myc (Myc) oncoprotein is among the most attractive of cancer targets given
that it is de-regulated in the majority of tumors and that its inhibition profoundly affects their …

Targeting intrinsically disordered transcription factors: changing the paradigm

K Tsafou, PB Tiwari, JD Forman-Kay, SJ Metallo… - Journal of molecular …, 2018 - Elsevier
Increased understanding of intrinsically disordered proteins (IDPs) and protein regions has
revolutionized our view of the relationship between protein structure and function. Data now …

[HTML][HTML] Premature aging and reduced cancer incidence associated with near-complete body-wide Myc inactivation

H Wang, J Lu, T Stevens, A Roberts, J Mandel, R Avula… - Cell reports, 2023 - cell.com
MYC proto-oncogene dysregulation alters metabolism, translation, and other functions in
ways that support tumor induction and maintenance. Although Myc+/− mice are healthier …